

Walter Reinisch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3395385/publications.pdf>

Version: 2024-02-01

133
papers

11,829
citations

76326

40
h-index

29157

104
g-index

137
all docs

137
docs citations

137
times ranked

8978
citing authors

#	ARTICLE	IF	CITATIONS
1	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 376, 1723-1736.	27.0	1,232
2	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. <i>Gastroenterology</i> , 2021, 160, 1570-1583.	1.3	1,054
3	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. <i>Lancet, The</i> , 2016, 388, 1281-1290.	13.7	771
4	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , 2011, 60, 780-787.	12.1	750
5	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2779-2789.	13.7	633
6	Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. <i>Gastroenterology</i> , 2020, 159, 481-491.e3.	1.3	613
7	Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial. <i>Gastroenterology</i> , 2012, 142, 1102-1111.e2.	1.3	485
8	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , 2012, 61, 535-542.	12.1	463
9	Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. <i>Gut</i> , 2014, 63, 88-95.	12.1	411
10	Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity. <i>Gastroenterology</i> , 2013, 145, 987-995.	1.3	354
11	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	1.3	331
12	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	1.3	323
13	Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 147, 1296-1307.e5.	1.3	280
14	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	1.3	251
15	Effect of IBD medications on COVID-19 outcomes: results from an international registry. <i>Gut</i> , 2021, 70, 725-732.	12.1	240
16	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 135-144.	13.7	157
17	Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC. <i>Gastroenterology</i> , 2013, 145, 978-986.e5.	1.3	155
18	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 139-147.	4.4	138

#	ARTICLE	IF	CITATIONS
19	Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. <i>BMJ, The</i> , 2021, 374, n1554.	6.0	136
20	Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1068-1076.	3.7	132
21	Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 921-929.	1.3	130
22	Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	1.3	126
23	A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED). <i>American Journal of Gastroenterology</i> , 2013, 108, 1877-1888.	0.4	123
24	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	1.3	114
25	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. <i>Gastroenterology</i> , 2021, 161, 715-718.e4.	1.3	102
26	Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021, 160, 2340-2353.	1.3	93
27	Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study. <i>Gastroenterology</i> , 2022, 162, 1650-1664.e8.	1.3	88
28	Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study. <i>Gut</i> , 2018, 67, 1824-1835.	12.1	87
29	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
30	52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1700-1709.	1.9	75
31	State of the iron: How to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 429-440.	1.3	71
32	Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn’s Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 539-547.e2.	4.4	71
33	Efficacy and Safety of Abruimab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, 946-957.e18.	1.3	66
34	Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 418-428.	1.3	60
35	Burden and outcomes for complex perianal fistulas in Crohn’s disease: Systematic review. <i>World Journal of Gastroenterology</i> , 2018, 24, 4821-4834.	3.3	59
36	Open : Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-up in the PYRAMID Registry. <i>American Journal of Gastroenterology</i> , 2018, 113, 872-882.	0.4	58

#	ARTICLE	IF	CITATIONS
37	Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2018, 155, 1008-1011.e8.	1.3	56
38	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 118-127.	8.1	49
39	Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. <i>Gastroenterology</i> , 2022, 162, 316-319.e5.	1.3	46
40	Competition for Clinical Trials in Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 157, 1457-1461.e2.	1.3	44
41	Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affairs Healthcare System. <i>Gut</i> , 2021, 70, 1657-1664.	12.1	42
42	Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 293-300.	1.9	41
43	Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 411-418.e3.	4.4	40
44	Biosimilar safety factors in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S9-S15.	3.4	39
45	Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S669-S677.	1.3	39
46	Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 790-802.	2.0	37
47	Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1255-1261.	1.9	36
48	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1063-1075.	8.1	35
49	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. <i>Digestive and Liver Disease</i> , 2015, 47, 356-364.	0.9	33
50	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0233781.	2.5	32
51	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 914-929.	1.3	29
52	A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1226-1233.	1.5	28
53	Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 803-810.	1.9	28
54	Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2022, 117, 1106-1117.	0.4	28

#	ARTICLE	IF	CITATIONS
55	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1562-1571.	1.9	27
56	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1673-1679.e1.	4.4	26
57	MANTA and MANTA-RAY: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. <i>Advances in Therapy</i> , 2022, 39, 3403-3422.	2.9	26
58	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating $\gamma\delta$ T Cells in Crohn's Disease: Report of the TOSCA Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 188-196.	1.3	24
59	Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. <i>Journal of Rheumatology</i> , 2022, 49, 320-329.	2.0	24
60	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1236-1245.	0.4	23
61	Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 116-125.e5.	4.4	23
62	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 938-949.	1.3	23
63	Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 591-600.	1.3	23
64	Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1579-1587.e2.	4.4	22
65	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. <i>Gut</i> , 2020, 69, 658-664.	12.1	21
66	The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. <i>United European Gastroenterology Journal</i> , 2021, 9, 581-589.	3.8	21
67	Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1095-1104.e9.	4.4	21
68	Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2018, 50, 1019-1029.	0.9	20
69	Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110057.	3.2	20
70	INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1737-1745.	1.9	19
71	Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). <i>Gut</i> , 2022, 71, 1078-1087.	12.1	18
72	Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 11, 171-178.	1.3	17

#	ARTICLE	IF	CITATIONS
73	Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1053-1066.	1.3	17
74	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 304-313.	1.9	17
75	Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. <i>Gut</i> , 2021, 70, gutjnl-2020-320690.	12.1	17
76	Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1522-1531.	1.9	16
77	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 462-470.	1.3	16
78	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 106-122.	1.9	14
79	External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. <i>Pharmaceutics</i> , 2021, 13, 1368.	4.5	13
80	Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1588-1597.e3.	4.4	12
81	Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE). <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3430-3441.	3.0	11
82	Impact of various central endoscopy reading models on treatment outcome in Crohn's disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 174-182.e2.	1.0	11
83	Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 848-854.	1.9	11
84	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 234-245.	1.9	11
85	Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 832-840.	2.8	11
86	Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1148-1157.	1.3	10
87	Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1649-1657.	1.3	10
88	Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1034-1044.	1.9	10
89	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. <i>Advances in Therapy</i> , 2022, 39, 2342-2364.	2.9	10
90	New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry. <i>Inflammatory Bowel Diseases</i> , 2021, , .	1.9	9

#	ARTICLE	IF	CITATIONS
91	End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease. Journal of Crohn's and Colitis, 2021, 15, 1114-1119.	1.3	9
92	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	4.4	9
93	Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous Thromboembolism. Inflammatory Bowel Diseases, 2021, 27, 1773-1783.	1.9	8
94	Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection. Journal of Clinical Pharmacology, 2021, 61, 224-233.	2.0	8
95	Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohn's and Colitis, 2019, 13, 1227-1233.	1.3	7
96	Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. Journal of Crohn's and Colitis, 2020, 14, S815-S819.	1.3	7
97	The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. Inflammatory Bowel Diseases, 2022, , .	1.9	7
98	Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. Inflammatory Bowel Diseases, 2023, 29, 1-8.	1.9	7
99	Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflammatory Bowel Diseases, 2019, 25, 163-171.	1.9	6
100	Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management. British Journal of Clinical Pharmacology, 2021, 87, 2374-2384.	2.4	6
101	Immunologically relevant aspects of the new COVID-19 vaccines – an –GAI (Austrian Society for) Tj ETQq1 1 0.784314 rgBT /Over Allergo Journal International, 2021, 30, 155-168.	2.0	6
102	Role of fecal calprotectin in predicting endoscopic recurrence in postoperative Crohn's disease. Scandinavian Journal of Gastroenterology, 2021, 56, 1169-1174.	1.5	6
103	Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. Journal of Crohn's and Colitis, 2022, 16, 1011-1019.	1.3	6
104	Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2022, 11, 3316.	2.4	6
105	Passive Smoking Increases the Risk for Intestinal Surgeries in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2021, 27, 379-385.	1.9	5
106	Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflammatory Bowel Diseases, 2022, 28, 1555-1564.	1.9	5
107	The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. Inflammatory Bowel Diseases, 2023, 29, 716-725.	1.9	5
108	COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. Clinical Gastroenterology and Hepatology, 2021, 19, 2210-2213.e3.	4.4	4

#	ARTICLE	IF	CITATIONS
109	Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments. <i>American Journal of Gastroenterology</i> , 2017, 112, S329-S330.	0.4	4
110	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1442-1453.	3.7	4
111	Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1151-1159.	3.7	4
112	Inflammatory Bowel Disease Patients' Perspectives of Clinical Trials: A Global Quantitative and Qualitative Analysis. <i>Crohn's & Colitis</i> 360, 2021, 3, .	1.1	3
113	Precision Medicine in Inflammatory Bowel Diseases: Challenges and Considerations for the Path Forward. <i>Gastroenterology</i> , 2022, 162, 1815-1821.	1.3	3
114	Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. <i>United European Gastroenterology Journal</i> , 2022, 10, 485-495.	3.8	3
115	PEG and Mucosal Biofilms in Irritable Bowel Syndrome and Ulcerative Colitis. <i>Gastroenterology</i> , 2022, 162, 992-993.	1.3	2
116	Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 616-624.	1.3	2
117	Letter to the Editor Regarding Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. <i>Advances in Therapy</i> , 2021, 39, 811.	2.9	2
118	A Review of the Totality of Evidence for the Development and Approval of ABP710 (AVSOLA), an Infliximab Biosimilar. <i>Advances in Therapy</i> , 2022, 39, 44-57.	2.9	2
119	P-141 Association Between Week 8 Mayo Subscores and Hospitalisation Rates in Adalimumab-treated Patients with Ulcerative Colitis from ULTRA1 and ULTRA2. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S80.	1.9	1
120	Introduction and commentary: Biosimilars' clinical trial and safety considerations. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S1.	3.4	1
121	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1209-1210.	3.7	1
122	Clinical Decision Support Tool for Infliximab in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1192-e1195.	4.4	1
123	Editorial: is it not just PRO, but the most important individual PRO, that really matters in Crohn's disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1040-1041.	3.7	1
124	Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. <i>Vaccines</i> , 2022, 10, 759.	4.4	1
125	Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib. <i>Tissue Barriers</i> , 2023, 11, .	3.2	1
126	PWE-049...Assessment of symptomatic hypophosphatemia with iron isomaltoside in inflammatory bowel disease patients. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
127	Response to Letter by Moulton et al.. Inflammatory Bowel Diseases, 2019, 25, e99-e99.	1.9	0
128	Reply. Gastroenterology, 2020, 158, 2307.	1.3	0
129	P117â€¦Filgotinib reduces markers of JAK1 signaling in Crohnâ€™s disease: concordance with endoscopy and histopathology. , 2021, , .		0
130	Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab. Inflammatory Bowel Diseases, 2021, 27, 1963-1967.	1.9	0
131	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
132	Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
133	Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210908.	3.2	0